Organovo Signs Exclusive Distributor Agreement With Cosmo Bio (Japan)
December 14 2016 - 08:05AM
Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a
three-dimensional biology company focused on delivering scientific
and medical breakthroughs using its 3D bioprinting technology,
announced an exclusive distributor agreement with Cosmo Bio Co.,
Ltd. (JASDAQ:3386) (“CosmoBio”) for its NovoViewTM Preclinical
Services in Japan. CosmoBio is one of Japan’s largest
suppliers in the life science industry, and Organovo will work with
CosmoBio’s Drug Discovery Services (DDS) team to gain direct access
to customers and support projects throughout the Japanese
biopharmaceutical industry.
“We’re committed to expanding our customer footprint in Asia, as
four of the world’s Top 25 global pharmaceutical companies are
located in Japan,” said Paul Gallant, general manager,
Organovo. “CosmoBio is an ideal distribution partner for our
liver and kidney tissue testing services because of their deep
network, strong customer relationships and excellent track record
selling the products and services of leading research tools
companies.”
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional
human tissues for use in medical research and therapeutic
applications. The Company develops 3D human tissue models
through internal development and in collaboration with
pharmaceutical, academic and other partners.
Organovo's 3D human tissues have the potential to accelerate
the drug discovery process, enabling treatments to be developed
faster and at lower cost. The Company’s ExVive Human Liver
and Kidney Tissues are used in toxicology and other preclinical
drug testing. The Company also actively conducts early
research on specific tissues for therapeutic use in direct surgical
applications. In addition to numerous scientific
publications, the Company's technology has been featured
in The Wall Street Journal, Time Magazine, The Economist,
Forbes, and numerous other media outlets. Organovo is
changing the shape of life science research and transforming
medical care. Learn more
at www.organovo.com.
About Cosmo Bio Co.,
Ltd.CosmoBio is an
organization established to sell and distribute biological reagents
and services for research purposes, headquartered in Tokyo, with a
network of over 200 contracted dealers throughout Japan.
CosmoBio is one of the largest and most established life sciences
reagents and services supplier in Japan. Learn more
at www.cosmobio.co.jp.
Forward-Looking Statements Any statements
contained in this press release that do not describe historical
facts constitute forward-looking statements as that term is defined
in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to a number of risks and
uncertainties. The factors that could cause the Company's
actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company's ability to develop, market
and sell products and services based on its technology; the
expected benefits and efficacy of the Company's products, services
and technology; the market acceptance of the Company's products and
services; the Company's business, research, product development,
regulatory approval, marketing and distribution plans and
strategies, including its use of third party distributors; the
Company's ability to successfully complete the contracts and
recognize the revenue represented by the contracts included in its
previously reported total contract bookings and secure additional
contracted collaborative relationships; the final results of the
Company's preclinical studies may be different from the Company's
studies or interim preclinical data results and may not support
further clinical development of its therapeutic tissues; the
Company may not successfully complete the required preclinical and
clinical trials required to obtain regulatory approval for its
therapeutic tissues on a timely basis or at all; and the Company’s
ability to meet its fiscal year 2017 outlook and/or its long-range
outlook. These and other factors are identified and described
in more detail in the Company's filings with the SEC,
including its Annual Report on Form 10-K filed with
the SEC on June 9, 2016 and its Quarterly Report on
Form 10-Q filed with the SEC on November 3, 2016. You should
not place undue reliance on these forward-looking statements, which
speak only as of the date that they were made. These
cautionary statements should be considered with any written or oral
forward-looking statements that the Company may issue in the
future. Except as required by applicable law, including the
securities laws of the United States, the Company does
not intend to update any of the forward-looking statements to
conform these statements to reflect actual results, later events or
circumstances or to reflect the occurrence of unanticipated
events.
Investor Contact:
Steve Kunszabo
Organovo Holdings, Inc.
+1 (858) 224-1092
skunszabo@organovo.com
Press Contact:
Jessica Yingling
Little Dog Communications
+1 (858) 344-8091
jessica@litldog.com
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Mar 2023 to Mar 2024